Employers train workers on equipment, procedures, hazards, harassment, cybersecurity, emergency response, and job-specific expectations. We train supervisors to recognize risk, follow process, document concerns, and respond to incidents.
U.S. Federal Marijuana 2026 Policy Update: What Employers Need to Know
Recent developments in U.S. federal marijuana policy have prompted questions from employers about whether workplace drug testing requirements may be changing. While there has been movement at the federal level regarding marijuana classification, there is currently no impact on Department of Transportation (DOT) testing protocols or workplace drug testing requirements.
Watch Now : Free Webinar - U.S. DOT Drug & Alcohol Testing Compliance
12 Things You Need to Know About the FMCSA Clearinghouse
The Federal Motor Carrier Safety Administration (FMCSA) Drug & Alcohol Clearinghouse is a critical tool for the commercial transportation industry. It helps improve safety by tracking drug and alcohol violations for drivers with commercial driver’s licenses (CDLs) and commercial learner’s permits (CLPs).
Common Issues to Watch Out for When Managing a DOT Random Drug and Alcohol Testing Program
For employers regulated by the Federal Motor Carrier Safety Administration (FMCSA), a compliant random drug and alcohol testing program is a required part of operating a safety-sensitive workforce. The rules are clear in principle. Drivers must be randomly selected for testing each year at the rates set by FMCSA. In practice, employers often encounter challenges that can affect compliance if the program is not carefully managed.
Important Update: 2026 DOT Random Drug and Alcohol Testing Rates
U.S. Federal Marijuana Policy Update: What Employers Should Know
On December 18, 2025, U.S. President Donald Trump signed an executive order directing U.S. federal authorities to reclassify marijuana from a Schedule I to a less restrictive Schedule III controlled substance under U.S. federal law. This is a significant shift in long-standing U.S. federal drug policy, but it does not currently affect any DOT testing protocols.
Impairing Prescription Medication Use & Fitness for Duty
At the recent Oil Sands Expo, DriverCheck’s Chief Medical Officer, Dr. Jonathan W. Davids, shared important insights during his presentation “Medication Madness: Impairing Prescription Medication Use & Fitness for Duty.” His talk highlighted the often-overlooked risks that prescription medications can pose in safety-sensitive industries.
DOT Proposes Changes to Drug Testing Panel
Real Cases Real Solutions: Ensuring Workplace Safety with Post-Incident Drug Testing
Understanding and Managing Alcohol Use in the Workplace
OEMAC’s 2025 Position on Cannabis Use in Safety-Sensitive and Decision-Critical Work
The Occupational and Environmental Medical Association of Canada (OEMAC) has released an updated 2025 position statement addressing the implications of cannabis use in the workplace - specifically within safety-sensitive and decision-critical roles. These roles require high cognitive function and judgment, and impairment can lead to serious safety, performance, or interpersonal consequences.